Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Corbus Pharmaceuticals Holdings

Nasdaq:CRBP
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CRBP
Nasdaq
$377M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • Corbus Pharmaceuticals Holdings has significant price volatility in the past 3 months.
CRBP Share Price and Events
7 Day Returns
13.3%
NasdaqGM:CRBP
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-25.2%
NasdaqGM:CRBP
1.6%
US Biotechs
-9.1%
US Market
CRBP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Corbus Pharmaceuticals Holdings (CRBP) 13.3% 7.2% -3.9% -25.2% -37% 79.3%
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • CRBP underperformed the Biotechs industry which returned 1.6% over the past year.
  • CRBP underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
CRBP
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Corbus Pharmaceuticals Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Corbus Pharmaceuticals Holdings to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Corbus Pharmaceuticals Holdings.

NasdaqGM:CRBP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:CRBP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.2
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.203 (1 + (1- 21%) (2.51%))
1.152
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.15
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.152 * 5.44%)
8.01%

Discounted Cash Flow Calculation for NasdaqGM:CRBP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Corbus Pharmaceuticals Holdings is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:CRBP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.01%)
2020 -145.39 Analyst x1 -134.61
2021 -168.28 Analyst x1 -144.26
2022 -99.51 Analyst x1 -78.98
2023 -14.36 Analyst x1 -10.55
2024 71.17 Analyst x1 48.42
2025 116.85 Est @ 64.19% 73.61
2026 169.96 Est @ 45.46% 99.14
2027 224.93 Est @ 32.34% 121.47
2028 277.02 Est @ 23.16% 138.52
2029 323.38 Est @ 16.73% 149.72
Present value of next 10 years cash flows $262.00
NasdaqGM:CRBP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $323.38 × (1 + 1.74%) ÷ (8.01% – 1.74%)
$5,251.35
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,251.35 ÷ (1 + 8.01%)10
$2,431.23
NasdaqGM:CRBP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $262.00 + $2,431.23
$2,693.23
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,693.23 / 72.49
$37.15
NasdaqGM:CRBP Discount to Share Price
Calculation Result
Value per share (USD) From above. $37.15
Current discount Discount to share price of $5.20
= -1 x ($5.20 - $37.15) / $37.15
86%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Corbus Pharmaceuticals Holdings is available for.
Intrinsic value
>50%
Share price is $5.2 vs Future cash flow value of $37.15
Current Discount Checks
For Corbus Pharmaceuticals Holdings to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Corbus Pharmaceuticals Holdings's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Corbus Pharmaceuticals Holdings's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Corbus Pharmaceuticals Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Corbus Pharmaceuticals Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:CRBP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.12
NasdaqGM:CRBP Share Price ** NasdaqGM (2020-03-27) in USD $5.2
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Corbus Pharmaceuticals Holdings.

NasdaqGM:CRBP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CRBP Share Price ÷ EPS (both in USD)

= 5.2 ÷ -1.12

-4.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Corbus Pharmaceuticals Holdings is loss making, we can't compare its value to the US Biotechs industry average.
  • Corbus Pharmaceuticals Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Corbus Pharmaceuticals Holdings's expected growth come at a high price?
Raw Data
NasdaqGM:CRBP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.65x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
56.3%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Corbus Pharmaceuticals Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Corbus Pharmaceuticals Holdings's assets?
Raw Data
NasdaqGM:CRBP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.10
NasdaqGM:CRBP Share Price * NasdaqGM (2020-03-27) in USD $5.2
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:CRBP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CRBP Share Price ÷ Book Value per Share (both in USD)

= 5.2 ÷ 0.10

54.62x

* Primary Listing of Corbus Pharmaceuticals Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Corbus Pharmaceuticals Holdings is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Corbus Pharmaceuticals Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Corbus Pharmaceuticals Holdings has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Corbus Pharmaceuticals Holdings expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
56.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Corbus Pharmaceuticals Holdings expected to grow at an attractive rate?
  • Corbus Pharmaceuticals Holdings's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Corbus Pharmaceuticals Holdings's earnings growth is expected to exceed the United States of America market average.
  • Corbus Pharmaceuticals Holdings's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:CRBP Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:CRBP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 56.3%
NasdaqGM:CRBP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 56.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:CRBP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:CRBP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 630 248 4
2023-12-31 403 104 4
2022-12-31 169 -2 -25 5
2021-12-31 56 -68 -114 5
2020-12-31 12 -51 -110 6
2020-03-28
NasdaqGM:CRBP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 36 -46 -71
2019-09-30 35 -37 -62
2019-06-30 34 -29 -56
2019-03-31 6 -18 -70
2018-12-31 5 -30 -56
2018-09-30 3 -25 -49
2018-06-30 3 -23 -41
2018-03-31 2 -23 -37
2017-12-31 2 -28 -32
2017-09-30 3 -24 -29
2017-06-30 3 -21 -28
2017-03-31 3 -18 -25

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Corbus Pharmaceuticals Holdings's earnings are expected to grow significantly at over 20% yearly.
  • Corbus Pharmaceuticals Holdings's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:CRBP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Corbus Pharmaceuticals Holdings Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CRBP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 2.90 6.53 0.92 3.00
2023-12-31 1.22 3.29 -0.15 3.00
2022-12-31 -0.33 0.19 -1.30 4.00
2021-12-31 -1.36 -0.60 -2.34 5.00
2020-12-31 -1.57 -0.75 -2.11 5.00
2020-03-28
NasdaqGM:CRBP Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.12
2019-09-30 -1.00
2019-06-30 -0.93
2019-03-31 -1.20
2018-12-31 -0.98
2018-09-30 -0.87
2018-06-30 -0.76
2018-03-31 -0.70
2017-12-31 -0.65
2017-09-30 -0.61
2017-06-30 -0.60
2017-03-31 -0.57

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Corbus Pharmaceuticals Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Corbus Pharmaceuticals Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Corbus Pharmaceuticals Holdings has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Corbus Pharmaceuticals Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Corbus Pharmaceuticals Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Corbus Pharmaceuticals Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Corbus Pharmaceuticals Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Corbus Pharmaceuticals Holdings's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Corbus Pharmaceuticals Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Corbus Pharmaceuticals Holdings Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CRBP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 36.14 -71.45 23.64
2019-09-30 35.50 -62.18 21.10
2019-06-30 34.00 -55.99 18.75
2019-03-31 5.76 -70.21 16.53
2018-12-31 4.82 -55.67 12.96
2018-09-30 2.89 -49.06 11.79
2018-06-30 2.60 -41.42 10.74
2018-03-31 2.10 -36.65 9.63
2017-12-31 2.44 -32.42 8.96
2017-09-30 2.82 -29.30 8.96
2017-06-30 2.76 -27.68 8.59
2017-03-31 2.81 -24.57 7.73
2016-12-31 1.91 -20.00 6.46
2016-09-30 1.90 -14.93 4.93
2016-06-30 1.33 -11.83 3.96
2016-03-31 1.04 -10.21 3.91
2015-12-31 0.65 -8.85 3.61
2015-09-30 0.28 -7.61 3.26
2015-06-30 0.11 -6.02 2.83
2015-03-31 -3.96 2.16
2014-12-31 -2.54 1.39
2014-09-30 -1.57 1.00 -0.02
2014-06-30 -0.97 0.65 0.01
2014-03-31 -0.67 0.37 0.19
2013-12-31 -0.60 0.35 0.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Corbus Pharmaceuticals Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Corbus Pharmaceuticals Holdings has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Corbus Pharmaceuticals Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Corbus Pharmaceuticals Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Corbus Pharmaceuticals Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Corbus Pharmaceuticals Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Corbus Pharmaceuticals Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Corbus Pharmaceuticals Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Corbus Pharmaceuticals Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Corbus Pharmaceuticals Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 50.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Corbus Pharmaceuticals Holdings Company Filings, last reported 2 months ago.

NasdaqGM:CRBP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 6.16 0.75 31.75
2019-09-30 29.64 0.00 54.85
2019-06-30 47.37 0.10 73.15
2019-03-31 42.30 0.25 89.92
2018-12-31 27.52 0.39 41.75
2018-09-30 42.87 0.00 55.66
2018-06-30 55.49 0.08 64.68
2018-03-31 65.54 0.21 70.96
2017-12-31 57.78 0.33 62.54
2017-09-30 31.98 0.00 36.60
2017-06-30 37.59 0.04 43.03
2017-03-31 43.59 0.16 48.93
2016-12-31 8.92 0.27 14.99
2016-09-30 13.31 0.00 18.91
2016-06-30 17.65 0.02 22.03
2016-03-31 6.40 0.09 9.69
2015-12-31 8.99 0.16 12.34
2015-09-30 11.17 0.00 13.17
2015-06-30 6.77 0.00 9.24
2015-03-31 4.69 0.07 4.97
2014-12-31 5.86 0.14 6.26
2014-09-30 7.02 0.08 7.54
2014-06-30 7.45 0.64 8.50
2014-03-31 -0.79 0.64 0.16
2013-12-31 -0.67 0.64 0.30
  • Corbus Pharmaceuticals Holdings's level of debt (12.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (2.5% vs 12.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Corbus Pharmaceuticals Holdings has less than a year of cash runway based on current free cash flow.
  • Corbus Pharmaceuticals Holdings has less than a year of cash runway if free cash flow continues to grow at historical rates of 44% each year.
X
Financial health checks
We assess Corbus Pharmaceuticals Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Corbus Pharmaceuticals Holdings has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Corbus Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Corbus Pharmaceuticals Holdings dividends.
If you bought $2,000 of Corbus Pharmaceuticals Holdings shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Corbus Pharmaceuticals Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Corbus Pharmaceuticals Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:CRBP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:CRBP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Corbus Pharmaceuticals Holdings has not reported any payouts.
  • Unable to verify if Corbus Pharmaceuticals Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Corbus Pharmaceuticals Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Corbus Pharmaceuticals Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Corbus Pharmaceuticals Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Corbus Pharmaceuticals Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Corbus Pharmaceuticals Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Corbus Pharmaceuticals Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yuval Cohen
COMPENSATION $3,572,460
AGE 44
TENURE AS CEO 5.9 years
CEO Bio

Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc (formerly, Morria Biopharmaceuticals Plc) from February 2013 to June 2013 and served as its President and Co-founder since January 12, 2005 until February 2013. Dr. Cohen served as the Managing Director of Celsus Therapeutics Plc. Dr. Cohen has been the driving force behind transforming MFAID technology into the biotech start-up that is Morria. Dr. Cohen's background in both molecular biology and protein biochemistry and his interest in biotechnology enable him to understand and convey both the nature and potential of this technology. His responsibility is to develop the anti-inflammatory propriety technology platform to its full potential with various strategic partners. Dr. Cohen is committed to making Morria an unprecedented success. Dr. Cohen served as an Interim Chief Executive Officer at Celsus Therapeutics Plc. He served as a Director of Celsus Therapeutics Plc from January 12, 2005 to December 10, 2013. Dr. Cohen worked in the laboratories of Wolf Brandt (University of Cape Town) and Dietrich Averbeck (Curie Institute) on chromatin and DNA repair processes. He is also a recipient of a certificate in Business Management and Entrepreneurship from the Cape Technikon (awarded with distinction, 2002). Dr. Cohen Awards includes: Amelia Schenkman Foundation Merit bursary, Dean's List, Foundation for Research and Development bursary, Boursier du Gouvernement Français (French Ministry of Foreign Affairs), Young Scientist travel award Brussels 2001 (L-MOV), San Francisco 2000 (ASP). Dr. Cohen holds Israeli and South African nationalities and is fluent in English, French, Hebrew and Romanian. He holds BS in Microbiology and Biochemistry from University of Cape Town. Dr. Cohen holds a PhD (cum laude) from the Curie Institute and the University of Paris V in Medical Science.

CEO Compensation
  • Yuval's compensation has increased whilst company is loss making.
  • Yuval's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Corbus Pharmaceuticals Holdings management team in years:

5.6
Average Tenure
61
Average Age
  • The average tenure for the Corbus Pharmaceuticals Holdings management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Yuval Cohen

TITLE
CEO & Director
COMPENSATION
$4M
AGE
44
TENURE
5.9 yrs

Mark Tepper

TITLE
Co-Founder & Consultant
COMPENSATION
$2M
AGE
62
TENURE
0.9 yrs

Barbara White

TITLE
Head of Research & Chief Medical Officer
COMPENSATION
$2M
AGE
69
TENURE
5.6 yrs

Sean Moran

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
61
TENURE
5.9 yrs

Robert Discordia

TITLE
Chief Operating Officer

Ted Jenkins

TITLE
Senior Director of Investor Relations & Communications

Scott Constantine

TITLE
Senior Director & Head of Clinical Operations

Craig Millian

TITLE
Chief Commercial Officer
AGE
51
TENURE
1.1 yrs

Sergei Atamas

TITLE
Executive Director of Research
Board of Directors Tenure

Average tenure and age of the Corbus Pharmaceuticals Holdings board of directors in years:

5.2
Average Tenure
51
Average Age
  • The tenure for the Corbus Pharmaceuticals Holdings board of directors is about average.
Board of Directors

Alan Holmer

TITLE
Chairman
COMPENSATION
$239K
AGE
69
TENURE
5.9 yrs

Yuval Cohen

TITLE
CEO & Director
COMPENSATION
$4M
AGE
44
TENURE
5.9 yrs

Chip Catlin

TITLE
Independent Director
COMPENSATION
$214K
AGE
71
TENURE
5.6 yrs

George Kunos

TITLE
Member of Scientific Advisory Board
TENURE
1.5 yrs

David Hochman

TITLE
Director
COMPENSATION
$205K
AGE
44
TENURE
6.3 yrs

Charles Serhan

TITLE
Member of Scientific Advisory Board
TENURE
4.8 yrs

Michael Knowles

TITLE
Member of Scientific Advisory Board

John Jenkins

TITLE
Independent Director
COMPENSATION
$325K
AGE
61
TENURE
1.8 yrs

Rachelle Jacques

TITLE
Independent Director
AGE
46
TENURE
0.9 yrs

Pete Salzmann

TITLE
Director
AGE
51
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Corbus Pharmaceuticals Holdings individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
18. Mar 20 Buy Craig Millian Individual 17. Mar 20 17. Mar 20 2,000 $4.25 $8,500
18. Mar 20 Buy Robert Discordia Individual 17. Mar 20 17. Mar 20 2,840 $3.54 $10,054
18. Mar 20 Buy Barbara White Individual 17. Mar 20 17. Mar 20 15,606 $3.63 $56,650
17. Mar 20 Buy Yuval Cohen Individual 17. Mar 20 17. Mar 20 4,300 $3.49 $15,007
13. Nov 19 Buy Barbara White Individual 12. Nov 19 12. Nov 19 3,424 $4.38 $14,992
12. Nov 19 Buy Yuval Cohen Individual 12. Nov 19 12. Nov 19 1,430 $4.26 $6,092
12. Nov 19 Buy Craig Millian Individual 11. Nov 19 11. Nov 19 1,000 $4.38 $4,380
12. Nov 19 Buy Robert Discordia Individual 11. Nov 19 11. Nov 19 2,500 $4.62 $11,559
16. Aug 19 Buy Craig Millian Individual 15. Aug 19 15. Aug 19 1,500 $5.48 $8,213
13. Aug 19 Buy Barbara White Individual 12. Aug 19 12. Aug 19 1,639 $6.10 $9,998
13. Aug 19 Buy Craig Millian Individual 12. Aug 19 12. Aug 19 1,500 $6.00 $9,000
12. Aug 19 Buy Yuval Cohen Individual 12. Aug 19 12. Aug 19 1,175 $6.06 $7,116
12. Aug 19 Buy Robert Discordia Individual 12. Aug 19 12. Aug 19 15,000 $5.86 $87,894
20. May 19 Buy Barbara White Individual 17. May 19 17. May 19 1,389 $7.20 $10,001
15. May 19 Buy Craig Millian Individual 14. May 19 14. May 19 1,000 $7.23 $7,227
14. May 19 Buy Sean Moran Individual 14. May 19 14. May 19 100 $7.12 $712
14. May 19 Buy Yuval Cohen Individual 13. May 19 13. May 19 995 $6.99 $6,955
X
Management checks
We assess Corbus Pharmaceuticals Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Corbus Pharmaceuticals Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Percentage Of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Do Insiders Own?

With a market capitalization of US$329m, Corbus Pharmaceuticals Holdings is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for Corbus Pharmaceuticals Holdings NasdaqGM:CRBP Ownership Summary, September 4th 2019 What Does The Institutional Ownership Tell Us About Corbus Pharmaceuticals Holdings? … Insider Ownership Of Corbus Pharmaceuticals Holdings The definition of company insiders can be subjective, and does vary between jurisdictions.

Simply Wall St -

Robert Discordia Is The Chief Operating Officer of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) And They Just Spent US$88k On Shares

See our latest analysis for Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings Insider Transactions Over The Last Year In fact, the recent purchase by Robert Discordia was the biggest purchase of Corbus Pharmaceuticals Holdings shares made by an insider individual in the last twelve months, according to our records. … Corbus Pharmaceuticals Holdings insiders may have bought shares in the last year, but they didn't sell any. … Insiders likely see value in Corbus Pharmaceuticals Holdings shares, given these transactions (along with notable insider ownership of the company).

Simply Wall St -

Update: Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Stock Gained 91% In The Last Three Years

Check out our latest analysis for Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … Over the last three years Corbus Pharmaceuticals Holdings has grown its revenue at 95% annually. … The share price rise of 24% per year throughout that time is nice to see, and given the revenue growth, that gain seems somewhat justified.

Simply Wall St -

How Does Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Affect Your Portfolio Volatility?

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … If this beta value holds true in the future, Corbus Pharmaceuticals Holdings shares are likely to rise more than the market when the market is going up, but fall faster when the market is going down. … What this means for you: Beta only tells us that the Corbus Pharmaceuticals Holdings share price is sensitive to broader market movements.

Simply Wall St -

Is Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Paid Enough Relative To Peers?

First, this article will compare CEO compensation with compensation at similar sized companies. … See our latest analysis for Corbus Pharmaceuticals Holdings How Does Yuval Cohen's Compensation Compare With Similar Sized Companies? … If you want to buy a stock that is better than Corbus Pharmaceuticals Holdings, this free list of high return, low debt companies is a great place to look.

Simply Wall St -

Could Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Investor Composition Influence The Stock Price?

As Charlie Munger said 'Show me the incentive and I will show you the outcome.' Corbus Pharmaceuticals Holdings is not a large company by global standards. … View our latest analysis for Corbus Pharmaceuticals Holdings NasdaqGM:CRBP Ownership Summary, May 13th 2019 What Does The Institutional Ownership Tell Us About Corbus Pharmaceuticals Holdings? … Insider Ownership Of Corbus Pharmaceuticals Holdings The definition of an insider can differ slightly between different countries, but members of the board of directors always count.

Simply Wall St -

Is Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Potentially Underrated?

(NASDAQ:CRBP) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … In the case of CRBP, it

Simply Wall St -

How Should Investors Feel About Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Pay?

In 2014 Yuval Cohen was appointed CEO of Corbus Pharmaceuticals Holdings, Inc. … has a market capitalization of US$365m, and pays its CEO total annual compensation worth US$3.2m. … While this analysis focuses on total compensation, it's worth noting the salary is lower, valued at US$463k

Simply Wall St -

How Financially Strong Is Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)?

(NASDAQ:CRBP), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is CRBP right in choosing financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

Do Directors Own Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares?

Every investor in Corbus Pharmaceuticals Holdings, Inc. … Corbus Pharmaceuticals Holdings is not a large company by global standards. … Check out our latest analysis for Corbus Pharmaceuticals Holdings

Simply Wall St -

Company Info

Description

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis. The company also has a license to develop, manufacture, and market CRB-4001, a 2nd generation peripherally-restricted, CB1 inverse agonist, which is in a preclinical stage to treat liver, lung, heart, and kidney fibrotic diseases. In addition, it has a strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.

Details
Name: Corbus Pharmaceuticals Holdings, Inc.
CRBP
Exchange: NasdaqGM
Founded: 2009
$376,950,334
72,490,449
Website: http://www.corbuspharma.com
Address: Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive,
Norwood,
Massachusetts, 02062,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CRBP New Common Shares Nasdaq Global Market US USD 27. Oct 2014
DB 337 New Common Shares Deutsche Boerse AG DE EUR 27. Oct 2014
LSE 0SZI New Common Shares London Stock Exchange GB USD 27. Oct 2014
Number of employees
Current staff
Staff numbers
141
Corbus Pharmaceuticals Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:09
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.